Alcon Launches TRYPTYR in U.S. for Dry Eye Disease Treatment
TRYPTYR (acoltremon ophthalmic solution 0.003%) stimulates tear production via TRPM8 activation and is now available in the U.S. An intriguing…
Stuart Therapeutics Unveils Phase III Results for Novel Dry Eye Candidate
ST-100 missed its primary endpoint—but showed visible healing on the eye’s surface by Day 4. Stuart Therapeutics (Florida, United States)…
latest posts
